Scarica l'app Stockscreener
0.9489
0.11%
-0.000999
Dopo l'orario di chiusura:
.95
0.0011
+0.12%
Precedente Chiudi:
$0.9499
Aprire:
$0.9204
Volume 24 ore:
39,095
Relative Volume:
0.80
Capitalizzazione di mercato:
$3.60M
Reddito:
-
Utile/perdita netta:
$-736.70K
Rapporto P/E:
-94.89
EPS:
-0.01
Flusso di cassa netto:
$-4.14M
1 W Prestazione:
-5.11%
1M Prestazione:
-7.42%
6M Prestazione:
-25.28%
1 anno Prestazione:
-62.04%
Intervallo 1D:
$0.90
$0.9499
Intervallo di 1 settimana:
$0.90
$1.00
Portata 52W:
$0.802
$2.9799
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Nome
Xortx Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta XRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.9489 | 3.79M | 0 | -736.70K | -4.14M | -0.01 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Xortx Therapeutics Inc Borsa (XRTX) Ultime notizie
XORTX Therapeutics looks to raise $3M through private placement - MSN
XRTX Initiates $3 Million Private Placement to Fund Key Projects - GuruFocus
XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program - Nasdaq
MT Newswires Canada Stocks To Watch: Endeavour Mining; Quantum BioPharma; XORTX Therapeutics - marketscreener.com
XORTX Announces USD $3 Million Offering - GlobeNewswire
XORTX Therapeutics Announces $3 Million Offering to Advance Gout Programs - TipRanks
Late-Stage Biotech XORTX Secures $3M Funding to Advance Novel Gout Treatment Program - Stock Titan
XORTX Therapeutics Inc. announced that it expects to receive $2.999999 million in funding - marketscreener.com
XORTX Therapeutics reports Q1 financials to SEC By Investing.com - Investing.com South Africa
XORTX Therapeutics Reports Q1 2025 Financial Results - TipRanks
XORTX Therapeutics reports Q1 financials to SEC - Investing.com
XORTX Therapeutics Delays Yearly Report Filing - TipRanks
XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com
XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks
XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com
XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire
XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com
XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks
XORTX Announces Grant of European Patent - GlobeNewswire
XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan
XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire
XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail
1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail
XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks
XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
Xortx Therapeutics Inc Azioni (XRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):